Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Lung Neoplasms 2Stomach Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 9Cyclophosphamide 9Whole-Body Irradiation 8Mycophenolic Acid 8Cyclosporine 8Cord Blood Stem Cell Transplantation 7fludarabine 5Peripheral Blood Stem Cell Transplantation 4Busulfan 4Arsenic Trioxide 4Antilymphocyte Serum 4Transplantation 3Thiotepa 3Tacrolimus 3Radiotherapy 3Etoposide 3Cytarabine 3Methylprednisolone 2Methotrexate 2Melphalan 2Carmustine 2Azacitidine 2thymoglobulin 1lonafarnib 1lintuzumab 1itacitinib 1Vorinostat 1Tretinoin 1Tetradecanoylphorbol Acetate 1Teriparatide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia, Refractory, with Excess of Blasts × lonafarnib × Clear all
NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
47 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡